NASDAQ
ADAG

Adagene Inc

Biotechnology
Healthcare

Prices are adjusted according to historical splits.

Adagene Inc Stock Price

Vitals

Today's Low:
$1.3123
Today's High:
$1.42
Open Price:
$1.3123
52W Low:
$0.9
52W High:
$6.06
Prev. Close:
$1.44
Volume:
5254

Company Statistics

Market Cap.:
$73.53 million
Book Value:
2.595
Revenue TTM:
$12.74 million
Operating Margin TTM:
-651%
Gross Profit TTM:
$10.18 million
Profit Margin:
0%
Return on Assets TTM:
-26.15%
Return on Equity TTM:
-55.96%

Company Profile

Adagene Inc had its IPO on 2021-02-09 under the ticker symbol ADAG.

The company operates in the Healthcare sector and Biotechnology industry. Adagene Inc has a staff strength of 259 employees.

Stock update

Shares of Adagene Inc opened at $1.31 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $1.31 - $1.42, and closed at $1.4.

This is a -2.78% slip from the previous day's closing price.

A total volume of 5,254 shares were traded at the close of the day’s session.

In the last one week, shares of Adagene Inc have increased by +1.45%.

Adagene Inc's Key Ratios

Adagene Inc has a market cap of $73.53 million, indicating a price to book ratio of 0.4335 and a price to sales ratio of 4.4993.

In the last 12-months Adagene Inc’s revenue was $12.74 million with a gross profit of $10.18 million and an EBITDA of $-81676016. The EBITDA ratio measures Adagene Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Adagene Inc’s operating margin was -651% while its return on assets stood at -26.15% with a return of equity of -55.96%.

In Q2, Adagene Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 188.7%.

Adagene Inc’s PE and PEG Ratio

Forward PE
0
Trailing PE
0
PEG

Its diluted EPS in the last 12-months stands at $-1.91 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Adagene Inc’s profitability.

Adagene Inc stock is trading at a EV to sales ratio of 0.0853 and a EV to EBITDA ratio of 1.2618. Its price to sales ratio in the trailing 12-months stood at 4.4993.

Adagene Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$178.56 million
Total Liabilities
$56.46 million
Operating Cash Flow
$0
Capital Expenditure
$0
Dividend Payout Ratio
0%

Adagene Inc ended 2024 with $178.56 million in total assets and $0 in total liabilities. Its intangible assets were valued at $178.56 million while shareholder equity stood at $112.68 million.

Adagene Inc ended 2024 with $0 in deferred long-term liabilities, $56.46 million in other current liabilities, 5657.00 in common stock, $-226476058.00 in retained earnings and $0 in goodwill. Its cash balance stood at $168.04 million and cash and short-term investments were $168.04 million. The company’s total short-term debt was $7,609,251 while long-term debt stood at $9.26 million.

Adagene Inc’s total current assets stands at $175.01 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $1.87 million compared to accounts payable of $4.67 million and inventory worth $0.

In 2024, Adagene Inc's operating cash flow was $0 while its capital expenditure stood at $0.

Comparatively, Adagene Inc paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$1.4
52-Week High
$6.06
52-Week Low
$0.9
Analyst Target Price
$12.53

Adagene Inc stock is currently trading at $1.4 per share. It touched a 52-week high of $6.06 and a 52-week low of $6.06. Analysts tracking the stock have a 12-month average target price of $12.53.

Its 50-day moving average was $1.35 and 200-day moving average was $1.45 The short ratio stood at 0.38 indicating a short percent outstanding of 0%.

Around 1067.6% of the company’s stock are held by insiders while 971.1% are held by institutions.

Frequently Asked Questions About Adagene Inc

The stock symbol (also called stock or share ticker) of Adagene Inc is ADAG

The IPO of Adagene Inc took place on 2021-02-09

Similar Industry Stocks (Biotechnology)

Last Price
Chg
Chg%
$0.06
0.01
+10.73%
$82.18
-0.99
-1.19%
$1272.8
-68.05
-5.08%
$0.02
-0.01
-23.33%
$4.07
0.09
+2.26%
$38.82
-2.8
-6.73%
James Warren Tea Ltd (JAMESWARREN)
$249.65
0.6
+0.24%
$3.92
0.17
+4.53%
$461.2
-17.3
-3.62%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

Adagene Inc., a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company’s product candidates include ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin’s lymphoma; ADG126, a fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase I clinical trial for the treatment of advanced metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody, which is in preclinical; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical stage for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a CD20xCD3 POWERbody, which is in preclinical stage for the treatment off-tumor toxicities. The company was incorporated in 2011 and is headquartered in Suzhou, China.

Address

Building C14, Suzhou, China, 215123